Your session is about to expire
← Back to Search
Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression (PPMI Trial)
Phase 2
Waitlist Available
Research Sponsored by Ken Marek, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up study intervals ranging from 3 months to 156 months
Awards & highlights
All Individual Drugs Already Approved
No Placebo-Only Group
Approved for 5 Other Conditions
Summary
This trial observes and collects data on various health indicators in people with Parkinson's disease and healthy individuals. The goal is to identify markers that show how the disease progresses. This information can help in developing new treatments for Parkinson's disease.
Eligible Conditions
- Parkinson's Disease
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ study intervals ranging from 3 months to 156 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~study intervals ranging from 3 months to 156 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Mean Rates of Change
Secondary study objectives
Comparison between Rates of Change
Exploratory Analysis
Predictive Value
+2 moreAwards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Datscan SPECT ImagingExperimental Treatment1 Intervention
Subjects will b injected with 3-5 mCi of dopamine transporter. Within a 4 hour (+/- 30 minutes) window following the injection, subjects will undergo SPECT imaging on the camera.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ioflupane I-123
FDA approved
Find a Location
Who is running the clinical trial?
Ken Marek, MDLead Sponsor
Institute for Neurodegenerative DisordersOTHER
48 Previous Clinical Trials
12,062 Total Patients Enrolled
Kenneth L Marek, MDStudy ChairInstitute for Neurodegenerative Disorders
5 Previous Clinical Trials
505,292 Total Patients Enrolled
John Q. Trojanowski, MD, PhDStudy DirectorUniversity of Pennsylvania
Arthur W. Toga, PhDStudy DirectorUniversity of California, Los Angeles
1 Previous Clinical Trials
2,996 Total Patients Enrolled
Andrew Singleton, PhDStudy DirectorLaboratory of Neurogenetics; National Institute on Aging NIH
1 Previous Clinical Trials
2,000 Total Patients Enrolled
Tatiana Froud, PhDStudy DirectorIndiana University
John P Seibyl, MDStudy DirectorInstitute for Neurodegenerative Disorders
3 Previous Clinical Trials
61 Total Patients Enrolled
Karl Kieburtz, MDStudy DirectorClinical Trials Coordination Center
2 Previous Clinical Trials
1,747 Total Patients Enrolled
Christopher Coffey, PhDStudy DirectorClinical Trials Statistical and Data Management Center, University of Iowa
1 Previous Clinical Trials
402 Total Patients Enrolled